New drug cocktail shows promise in shrinking HER2+ stomach tumors before surgery
NCT ID NCT05034887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests two approaches for HER2-positive stomach or gastroesophageal junction cancer that hasn't spread. One group gets trastuzumab deruxtecan alone before surgery. Another group gets a combination of trastuzumab deruxtecan, capecitabine, and durvalumab both before and after surgery. The main goal is to see how many patients have a major response in their tumor after treatment. The trial involves 64 adults aged 20 and older.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (T-DXd), capecitabine, durvalumab
What this could lead to
If successful, this could point toward a more effective treatment approach for HER2-positive stomach cancer, potentially improving surgical outcomes and reducing recurrence.
What could go wrong
This is a small, early-phase trial (64 participants) without a comparison group, so results may not apply broadly. The drug combination also carries risks like lung inflammation or heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan